|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06826 HAOHAI BIOTEC
Nominal 
27.000 -1.300 (-4.594%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 1,397,112 | 7.000% | 2,634,910 | 2,103,438 | 1,750,116 | 1,324,427 |
| Cost of Sales | (413,817) | 9.103% | (781,401) | (656,515) | (490,370) | (334,004) |
| Gross Profit | 983,295 | 6.140% | 1,853,509 | 1,446,923 | 1,259,746 | 990,423 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 473 | -- | 1,973 | (15,516) | 3,182 | 1,369 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 305 | -6.442% | 456 | 3,505 | 2,193 | (131) | |
| Profit / (Loss) before Taxation | 262,492 | 5.082% | 508,260 | 235,726 | 382,649 | 257,026 | |
| Taxation | (44,834) | 9.059% | (95,991) | (45,395) | (35,366) | (30,686) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 17,625 | -- | 3,852 | (9,861) | 4,951 | 3,732 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 235,283 | 14.641% | 416,121 | 180,470 | 352,234 | 230,072 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (29,236) | -17.501% | (70,436) | (80,280) | (93,247) | (103,554) |
| Depreciation & Amortisation | 98,572 | -3.146% | 197,855 | 204,217 | 162,837 | 132,871 |
| Directors' Emoluments | -- | -- | 9,007 | 9,714 | 5,621 | 4,850 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 101.000 | 17.442% | 174.286 | 74.286 | 142.857 | 92.857 |
| DPS (cts) | 40.000 | -- | 71.429 | 28.571 | 50.000 | 35.714 |
| Dividend Payout Ratio (%) | 39.604% | -- | 40.984% | 38.462% | 35.000% | 38.462% |
| Cash flow per share ($) | -- | -- | 3.720 | 1.333 | 1.943 | 1.479 |
| NBV per share ($) | 25.433 | -- | 23.535259 | 22.621076 | 23.211219 | 22.13217 |
| Remarks: | Real time quote last updated: 22/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 235,283 |
| %Change | 14.641% |
| EPS / (LPS) | RMB 1.010 |
| NBV Per Share (¥) | RMB 25.433 |